These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11235255)

  • 1. Celecoxib.
    O'Rourke ME
    Clin J Oncol Nurs; 2000; 4(3):143-4. PubMed ID: 11235255
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Food and Drug Administration.
    Henney JE
    JAMA; 2000 Mar; 283(9):1131. PubMed ID: 10703765
    [No Abstract]   [Full Text] [Related]  

  • 4. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
    Pérez-Segura P; Bodas A; Sereno M; Martínez-Amores B; Olivera H; Díaz S; López-Asenjo JA; Puente J; Maluenda C; Díaz-Rubio E
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):230-2. PubMed ID: 20197018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
    Raskov HH
    Ugeskr Laeger; 2006 Jan; 168(4):359-62. PubMed ID: 16436235
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
    Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
    Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial adenomatous polyposis-associated ampullary adenoma: response to chemotherapy for concurrent metastatic adenocarcinoma.
    Coté GA; Brunt EM; Jonnalagadda SS
    Clin Gastroenterol Hepatol; 2009 Jun; 7(6):e28-9. PubMed ID: 19245848
    [No Abstract]   [Full Text] [Related]  

  • 10. Cure crusader. How a cancer patient waged a determined quest for a medical miracle--and may still achieve it.
    Thompson D
    Time; 1999 Oct; 154(15):72-3. PubMed ID: 10620933
    [No Abstract]   [Full Text] [Related]  

  • 11. [A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer].
    MMW Fortschr Med; 2002 Nov; 144(46):14. PubMed ID: 12534075
    [No Abstract]   [Full Text] [Related]  

  • 12. Approach to angiogenesis inhibition based on cyclooxygenase-2.
    Masferrer J
    Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac and Erlotinib for Familial Adenomatous Polyposis.
    Matuchansky C
    JAMA; 2016 Aug; 316(5):544-5. PubMed ID: 27483077
    [No Abstract]   [Full Text] [Related]  

  • 14. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
    Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulindac and Erlotinib for Familial Adenomatous Polyposis--Reply.
    Samadder NJ; Neklason DW; Burt RW
    JAMA; 2016 Aug; 316(5):545. PubMed ID: 27483082
    [No Abstract]   [Full Text] [Related]  

  • 16. Despite positive studies, popularity of chemoprevention drugs increasing slowly.
    Zielinski SL
    J Natl Cancer Inst; 2004 Oct; 96(19):1410-2. PubMed ID: 15467023
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugging the Wnt pathway: problems and progress.
    Garber K
    J Natl Cancer Inst; 2009 Apr; 101(8):548-50. PubMed ID: 19351922
    [No Abstract]   [Full Text] [Related]  

  • 18. The STAMPEDE trial and celecoxib: how to adapt?
    Armstrong AJ
    Lancet Oncol; 2012 May; 13(5):443-5. PubMed ID: 22452892
    [No Abstract]   [Full Text] [Related]  

  • 19. The current status of chemoprevention in FAP.
    Wallace MH; Lynch PM
    Fam Cancer; 2006; 5(3):289-94; discussion 295-6. PubMed ID: 16998675
    [No Abstract]   [Full Text] [Related]  

  • 20. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
    Schönthal AH; Chen TC; Hofman FM; Louie SG; Petasis NA
    Expert Opin Investig Drugs; 2008 Feb; 17(2):197-208. PubMed ID: 18230053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.